Risk of Gastric and Colorectal Cancer After Tamoxifen Use for Breast Cancer: A Systematic Review and Meta-Analysis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Gastroenterology

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MCG.0000000000000262PMID 25319737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016cited by this paper
• Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

  2013cited by this paper
• The development of endocrine therapy for women with breast cancer.

  2013cited by this paper
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

  2013cited by this paper
• Gastric cancer: epidemiology and risk factors.

  2013cited by this paper
• Global cancer statistics

  2011cited by this paper
• Use of hormone replacement therapy and the risk of colorectal cancer.

  2009cited by this paper
• [Preliminary results of postoperative adjuvant treatment with tamoxifen in colorectal cancer].

  2007cited by this paper
• Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

  2007cited by this paper
• Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden

  2006cited by this paper
• Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Systematic Evaluation and Comparison of Statistical Tests for Publication Bias

  2005cited by this paper
• Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study

  2005cited by this paper
• Consensus Statement

  2004cited by this paper
• Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden.

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis.

  2003cited by this paper
• Gastric cancer epidemiology and risk factors.

  2003cited by this paper
• First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

  2002cited by this paper
• Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis

  2002cited by this paper
• Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  2002cited by this paper
• Epidemiology of colorectal cancer.

  2002cited by this paper
• Colorectal cancer following tamoxifen therapy for breast cancer (United States)

  2001cited by this paper
• Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.

  2000cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  1999cited by this paper
• Tamoxifen and risk of large bowel cancer in women with breast cancer

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• The hazards of scoring the quality of clinical trials for meta-analysis.

  1999cited by this paper
• Estrogen and progesterone receptors in gastric and colorectal cancer.

  1999cited by this paper
• Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen inhibits colorectal cancer metastases in the liver: A study in a murine model

  1998cited by this paper
• The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

  1998cited by this paper
• Tamoxifen: a Guide for Clinicians and Patients Craig Jordan, ed. Huntington (NY): PRR, Inc., 1996. 216 pp., illus. $39.95. ISBN 9641823-4-3

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Adenocarcinoma of the gastric cardia.

  1997cited by this paper
• Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.

  1997cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.

  1996cited by this paper
• The effect of tamoxifen on established human colorectal cancer cell lines in vitro.

  1996cited by this paper
• Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.

  1996cited by this paper
• Second cancers after adjuvant tamoxifen therapy for breast cancer.

  1996cited by this paper
• Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

  1995cited by this paper
• Hormones and colon cancer.

  1995cited by this paper
• Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists.

  1995cited by this paper
• Invited commentary: a critical look at some popular meta-analytic methods.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Synthesis of environmental evidence: nitrogen dioxide epidemiology studies.

  1992cited by this paper
• Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.

  1991cited by this paper
• [Epidemiology of colorectal cancer].

  1991cited by this paper
• An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials.

  1990cited by this paper
• Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

  1990cited by this paper
• Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation.

  1989cited by this paper
• Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.

  1989cited by this paper
• The effect of sex hormones and tamoxifen on the growth of human gastric and colorectal cancer cell lines

  1989cited by this paper
• [Endocrine therapy of scirrhous carcinoma of the stomach].

  1986cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper
• Controlled trial of tamoxifen as adjuvant agent in management of Early Breast Cancer:Interim analysis at four years by the Novaldex Adjuvant Trial Originisation.

  1983cited by this paper
• Logistic disease incidence models and case-control studies

  1979cited by this paper
• INFECTION IN INFANCY.

  1965cited by this paper
• TUMORS OF THE STOMACH

  1933cited by this paper

• Prognostic Factors Affecting Survival of Patients With Single Primary Breast Cancer vs Patients With Multiple Primary Cancers in Lifetime, One of Which is Breast Cancer

  2024cites this paper
• Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening

  2022cites this paper
• Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review

  2021cites this paper
• Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer

  2021cites this paper
• “The right measure for successful health care isn’t about the maximum possible for a few, but the average for everyone... and the minimum opportunities available to even those with the fewest

  2021cites this paper
• Long-term response on letrozole for gastric cancer

  2021cites this paper
• Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer

  2021cites this paper
• Adjuvant Surgical Oophorectomy Plus Tamoxifen: New Efficacy and Secondary Effects Data

  2020cites this paper
• Clinical practice to address tamoxifen nonadherence

  2020cites this paper
• Identifying risk factors and biomarkers for colorectal cancer screening

  2019cites this paper
• Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer

  2019cites this paper
• Increased risk of colorectal cancer in patients diagnosed with breast cancer in women.

  2016cites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper